Source: Eur Respir J 2014; 43: 1237-1239
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ryerson Christopher J.. Risk prediction and end-points in idiopathic pulmonary fibrosis: one step at a time. Eur Respir J 2014; 43: 1237-1239

Member's Comments

No comment yet.

Related content which might interest you: Targeted treatment of idiopathic pulmonary fibrosis: one step at a time Source: Eur Respir J 2016; 47:1321-1323 Year: 2016 A global registry for idiopathic pulmonary fibrosis: the time is now Source: Eur Respir J 2014; 44: 273-276 Year: 2014 Clinical course of idiopathic pulmonary fibrosis (IPF): Prediction and outcome Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Idiopathic pulmonary fibrosis: independent physiologic variables in the prediction of survival Source: Annual Congress 2007 - Clinical aspects of idiopathic pulmonary fibrosis Year: 2007 Idiopathic pulmonary fibrosis: another step in understanding the burden of this disease Source: Eur Respir J 2016; 48: 26-28 Year: 2016 Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment Source: ERJ Open Res, 7 (3) 00854-2020; 10.1183/23120541.00854-2020 Year: 2021 Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model Source: Eur Respir J, 52 (4) 1800497; 10.1183/13993003.00497-2018 Year: 2018 Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Challenges in idiopathic pulmonary fibrosis trials: the point on end-points Source: Eur Respir Rev 2011; 20: 195-200 Year: 2011 Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features Source: Eur Respir J 2006; 27: 143-150 Year: 2006 The six minute walking test: Clinical predictors of survival in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –The latest insights in exercise testing and physical inactivity Year: 2013 Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome Source: Eur Respir J 2011; 37: 356 Year: 2011 Accelerated variant of idiopathic pulmonary fibrosis: clinical and molecular behaviour Source: Eur Respir J 2007; 30: Suppl. 51, 488s Year: 2007 Idiopathic pulmonary fibrosis: time for greater expectations? Source: Eur Respir J, 52 (2) 1801312; 10.1183/13993003.01312-2018 Year: 2018 Non-invasive evaluation in prediction of pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward Source: Eur Respir J 2013; 42: 1446-1448 Year: 2013 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Nutritional assessment in patients with idiopathic pulmonary fibrosis: the NUTRIPF study Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine Source: Eur Respir J, 57 (1) 2003551; 10.1183/13993003.03551-2020 Year: 2021